Shots: The BORA P-III trial involves assessing of Fasenra (benralizumab) enrolling patients in ratio (1:1) who have completed one of the two SIROCCO or CALIMA P-III trials, administering Fasenra 30 mg SC q4w or q8w BORA results (N= 1926): improvement in efficacy outcomes; overall annual asthma exacerbation rate (eosinophil counts of 300 cells per μL) […]Read More
